Netherlands and her Ph.D. in epidemiology in 1993 from the University of Rotterdam. From 1995 to 2011, she was the head of Neuroepidemiology in the Department of Epidemiology at Erasmus Medical Center at the University of Rotterdam, and since 2002 she has held an adjunct professorship at the Harvard School of Public Health.

David J. Brooks, M.D., is the Harnett Professor of Neurology and Head of the Centre for Neuroscience in the Department of Medicine, Imperial College, London. He is also a Senior Neurologist in Global Clinical Development, Medical Diagnostics, GE Healthcare PLC. He has been a member of the Research Advisory Panels of the UK Parkinson’s Disease Society, the German dementia and Parkinson’s networks, and Inserm. He has been a member of the Scientific Advisory Board of the Michael J. Fox Foundation for Parkinson’s Disease Research (2002-2006), the UK Medical Research Council Neuroscience and Mental Health Board (2004-2007), and the UK Huntington’s Disease Association, and was Chairman of the Scientific Issues Committee of the Movement Disorder Society (1998-2002) and a Director of the International Society of Cerebral Blood Flow and Metabolism (1993-1997). His research involves the use of positron emission tomography and magnetic resonance imaging to diagnose and study the progression of Alzheimer’s and Parkinson’s diseases and their validation of biomarker therapeutic trials.

Charles S. DeCarli, M.D., is Director of the University of California, Davis, Alzheimer’s Disease Center. He has a strong interest in behavioral neurology, with specific emphasis on dementing disorders, including degenerative dementias such as Alzheimer’s disease and frontal dementias. He also focuses on dementias related to movement disorders and vascular disease, as well as cognitive impairment after closed head injury. Dr. DeCarli’s research interests are divided into two areas: using neuroimaging techniques to understand the relationship between brain structure and function with aging and disease; and studying the role of brain antioxidant systems, primarily quinone oxidoreductase, on the pathophysiology and potential treatment of Alzheimer’s disease. Dr. DeCarli earned a B.S. from the University of California, Santa Barbara, and an M.D. from the George Washington University Medical School.

Robert W. Mahley, M.D., Ph.D., is a Senior Investigator at both the Gladstone Institute of Cardiovascular Disease and the Gladstone Institute of Neurological Disease and President Emeritus of the Gladstone Institutes. Dr. Mahley is also a Professor of Pathology and Medicine at the University of California, San Francisco. Dr. Mahley is an internationally known expert on heart disease, cholesterol metabolism and, more recently, Alzheimer’s

The National Academies of Sciences, Engineering, and Medicine
500 Fifth St. N.W. | Washington, D.C. 20001

Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement